Literature DB >> 26305791

Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.

Qian Li, Mei Liu, Fei Ma, Yang Luo, Ruigang Cai, Liming Wang, Ningzhi Xu, Binghe Xu.   

Abstract

Entities:  

Year:  2015        PMID： 26305791      PMCID： PMC4549142          DOI： 10.1371/journal.pone.0136826

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


× No keyword cloud information.
There is an error in reference 29. The correct reference is: Mo W, Zhang J, Li X, Meng D, Gao Y, Yang S, et al. (2013) Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling through Critical Pathways to Regulate Cell Viability in Prostate Cancer. PLoS ONE 8(2): e56592.
  1 in total

1.  Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.

Authors:  Qian Li; Mei Liu; Fei Ma; Yang Luo; Ruigang Cai; Liming Wang; Ningzhi Xu; Binghe Xu
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240
  1 in total
  1 in total

1.  MicroRNA-19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 2.

Authors:  Fang Ma; Zhiyuan Wang; Jingjing Wang; Xianling Liu; Chunhong Hu
Journal:  Exp Ther Med       Date:  2017-06-23       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.